Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding

mBio

Volumn 5, Issue 5, 2014, Pages

  Costa, Isabella ^a,b   Pajon, Rolando ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; 4CMENB VACCINE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; COMPLEMENT FACTOR H, HUMAN; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; SERUM BACTERICIDAL ACTIVITY; TRANSGENIC MOUSE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; HUMAN; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; SERUM BACTERICIDAL ANTIBODY ASSAY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEISSERIA MENINGITIDIS; PROTEIN BINDING; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84908432781     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01625-14     Document Type: Article

References (47)

1. Harrison LH, Trotter CL, Ramsay ME. 2009. Global epidemiology of meningococcal disease. Vaccine 27:B51-B63. http://dx.doi.org/10.1016/ j.vaccine.2008.10.030.
2. Finne J, Leinonen M, Mäkelä PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
3. Granoff DM. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl 2):S54 -S65. http://dx.doi.org/10.1086/648966.
4. Martin NG, Snape MD. 2013. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev. Vaccines 12:837-858. http://dx.doi.org/ 10.1586/14760584.2013.814862.
5. Mcneil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS. 2013. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol. Mol. Biol. Rev. 77:234-252. http://dx.doi.org/10.1128/MMBR.00056-12.
6. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, Von Gottberg A, Du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389. http://dx.doi.org/10.1086/600141.
7. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789 -799. http://dx.doi.org/10.1084/ jem.20021911.
8. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O'Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Aricò B. 2010. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl. Acad. Sci. U. S. A. 107:3770-3775. http://dx.doi.org/ 10.1073/pnas.0915162107.
9. Kelly C, Arnold R, Galloway Y, O'Hallahan J. 2007. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166:817-823. http://dx.doi.org/10.1093/aje/kwm147.
10. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(Suppl 2):B87-B97. http://dx.doi.org/10.1016/ j.vaccine.2012.01.033.
11. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769. http://dx.doi.org/10.1128/IAI.01191-08.
12. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240. http://dx.doi.org/10.1016/j.tim.2007.03.005.
13. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839. http://dx.doi.org/10.1073/pnas.0603940103.
14. Bos MP, Grijpstra J, Tommassen-Van Boxtel R, Tommassen J. 2014. Involvement of Neisseria meningitidis lipoprotein GNA2091 in the assembly of a subset of outer membrane proteins. J. Biol. Chem. 289: 15602-15610. http://dx.doi.org/10.1074/jbc.M113.539510.
15. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137. http://dx.doi.org/10.1086/656741.
16. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Di s. J. 29:e71- e79. http://dx.doi.org/10.1097/ INF.0b013e3181b0602e.
17. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79:3751-3759. http://dx.doi.org/10.1128/IAI.05182-11.
18. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061. http://dx.doi.org/10.1086/528994.
19. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76:4232- 4240. http://dx.doi.org/10.1128/IAI.00367-08.
20. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606-3614.
21. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factorHand enhances meningococcal resistance to complement. PLoS Pathog. 6(7):e1001027. http://dx.doi.org/10.1371/ journal.ppat.1001027.
22. Langford-Smith A, Keenan TD, Clark SJ, Bishop PN, Day AJ. 2014. The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J. Innate Immun. 6:407-416. http://dx.doi.org/10.1159/000356513.
23. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088 -2100. http://dx.doi.org/10.1128/ IAI.72.4.2088-2100.2004.
24. Madico G, Welsch JA, Lewis LA, Mcnaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177: 501-510. http://dx.doi.org/10.4049/jimmunol.177.1.501.
25. Test ST, Mitsuyoshi J, Connolly CC, Lucas AH. 2001. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect. Immun. 69:3031-3040. http://dx.doi.org/10.1128/IAI.69.5.3031- 3040.2001.
26. Hostetter MK. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153:682-693. http:// dx.doi.org/10.1093/infdis/153.4.682.
27. Kerekes K, Cooper PD, Prechl J, Józsi M, Bajtay Z, Erdei A. 2001. Adjuvant effect of gamma-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J. Leukoc. Biol. 69:69-74. PubMed.
28. Giuntini S, Beernink PT, Reason DC, Granoff DM. 2012. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One 7(3):e34272. http:// dx.doi.org/10.1371/journal.pone.0034272.
29. Scarselli M, Aricò B, Brunelli B, Savino S, Di Marcello F, Palumbo E, Veggi D, Ciucchi L, Cartocci E, Bottomley MJ, Malito E, Lo Surdo P, Comanducci M, Giuliani MM, Cantini F, Dragonetti S, Colaprico A, Doro F, Giannetti P, Pallaoro M, Brogioni B, Tontini M, Hilleringmann M, Nardi-Dei V, Banci L, Pizza M, Rappuoli R. 2011. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3:91ra62. http://dx.doi.org/10.1126/scitranslmed.3002234.
30. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893. http://dx.doi.org/ 10.1038/nature07769.
31. Pajon R, Beernink PT, Granoff DM. 2012. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect. Immun. 80:2667-2677. http://dx.doi.org/ 10.1128/IAI.00103-12.
32. Reuter M, Caswell CC, Lukomski S, Zipfel PF. 2010. Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels. J. Biol. Chem. 285: 38473-38485. http://dx.doi.org/10.1074/jbc.M110.143727.
33. Fleury C, Su YC, Hallström T, Sandblad L, Zipfel PF, Riesbeck K. 2014. Identification of a Haemophilus influenzae factor H-binding lipoprotein involved in serum resistance. J. Immunol. 192:5913-5923. http:// dx.doi.org/10.4049/jimmunol.1303449.
34. Shaughnessy J, Lewis LA, Jarva H, Ram S. 2009. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77: 2094-2103. http://dx.doi.org/10.1128/IAI.01561-08.
35. Kopp A, Hebecker M, Svobodová E, Józsi M. 2012. Factor H: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules 2:46-75. http://dx.doi.org/10.3390/biom2010046.
36. Kopp A, Strobel S, Tortajada A, Rodríguez de Córdoba S, Sánchez- Corral P, Prohászka Z, López-Trascasa M, Józsi M. 2012. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factorHand factor H-related protein 1 to PENTRAXIN 3. J. Immunol. 189:1858 -1867. http://dx.doi.org/10.4049/ jimmunol.1200357.
37. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. 2005. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am Soc. Nephrol. 16:555-563. http://dx.doi.org/10.1681/ASN.2004050380.
38. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. 2010. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379-387. http://dx.doi.org/10.1182/blood-2009-05-221549.
39. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C. 2008. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514. http://dx.doi.org/10.1182/blood-2007-09-109876.
40. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3(3):e41. http://dx.doi.org/10.1371/ journal.pgen.0030041.
41. Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jönsen A, Nilsson SC, Hillarp A, Saxne T, Trouw LA, Blom AM. 2012. Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res. Ther. 14:R185. http://dx.doi.org/10.1186/ar4016.
42. Rossi R, Granoff DM, Beernink PT. 2013. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine 31:5451-5457. http://dx.doi.org/10.1016/ j.vaccine.2013.08.099.
43. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. 2012. The effect of human factorHon immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 8(5):e1002688. http://dx.doi.org/10.1371/ journal.ppat.1002688.
44. Van Der Veen S, Johnson S, Jongerius I, Malik T, Genovese A, Santini L, Staunton D, Ufret-Vincenty RL, Pickering MC, Lea SM, Tang CM. 2014. Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect. Immun 82:1157-1163. http://dx.doi.org/ 10.1128/IAI.01183-13.
45. Konar M, Granoff DM, Beernink PT. 2013. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J. Infect. Dis. 208:627-636. http://dx.doi.org/10.1093/infdis/jit239.
46. Frasch CE, Van Alphen L, Holst J, Poolman JT, Rosenqvist E. 2001. Outer membrane protein vesicle vaccines for meningococcal disease, p. 81-107. In Pollard AJ, Maiden MC (ed), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.
47. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4(5): e00339-13. http://dx.doi.org/10.1128/mBio.00339-13.